Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes : SMART Program 2001 Data
Open Access
- 1 July 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (7) , 2152-2157
- https://doi.org/10.1128/aac.47.7.2152-2157.2003
Abstract
This study evaluated the current status of antimicrobial resistance in clinical isolates of Streptococcus pyogenes in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. In 2001, 419 different isolates of S. pyogenes, including 275 from respiratory secretions, 87 from wound pus, and 31 from blood, were collected from nine hospitals in different parts of Taiwan. MICs of 23 antimicrobial agents were determined at a central location by the agar dilution method. All of the isolates were susceptible to penicillin (MIC at which 90% of the isolates were inhibited [MIC90], ≤0.03 μg/ml), cefotaxime (MIC90, ≤0.03 μg/ml), cefepime (MIC90, 0.06 μg/ml), meropenem (MIC90, ≤0.03 μg/ml), moxifloxacin (MIC90, 0.25 μg/ml), vancomycin (MIC90, 0.5 μg/ml), and linezolid (MIC90, 1 μg/ml). Overall, 78% of isolates were not susceptible to erythromycin (54% were intermediate, and 24% were resistant), and 5% were not susceptible to clindamycin. Of the 101 erythromycin-resistant isolates, 80.2% exhibited the M phenotype (mefA gene positive), 18.9% exhibited the cMLS (constitutive resistance to macrolides-lincosamides-streptogramin B [MLS]) phenotype (ermB gene positive), and 1% exhibited the iMLS (inducible resistance to MLS) phenotype (ermB gene positive). Fluoroquinolones (sitafloxacin > moxifloxacin > ciprofloxacin = levofloxacin = gatifloxacin > gemifloxacin) demonstrated potent activity against nearly all of the isolates of S. pyogenes tested. Thirty-two isolates (8%) were not susceptible to quinupristin-dalfopristin. Seventeen percent of isolates had telithromycin MICs of ≥1 μg/ml, and all of these isolates exhibited erythromycin MICs of ≥32 μg/ml. The high prevalence of resistance to telithromycin (which is not available in Taiwan) limits its potential use in the treatment of S. pyogenes infections, particularly in areas with high rates of macrolide resistance.Keywords
This publication has 42 references indexed in Scilit:
- Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and β-Lactams: SMART Program 2001 DataAntimicrobial Agents and Chemotherapy, 2003
- A Novel Efflux System in Inducibly Erythromycin-Resistant Strains of Streptococcus pyogenesAntimicrobial Agents and Chemotherapy, 2002
- Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000)Diagnostic Microbiology and Infectious Disease, 2002
- Erythromycin Resistance in Italian Isolates ofStreptococcus pyogenesand Correlations with Pulsed-Field Gel Electrophoresis AnalysisMicrobial Drug Resistance, 2002
- Increased Prevalence of Erythromycin Resistance in Streptococci: Substantial Upsurge in Erythromycin-Resistant M Phenotype inStreptococcus pyogenes(1979-1998) but Not inStreptococcus pneumoniae(1985-1999) in TaiwanMicrobial Drug Resistance, 2002
- Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and StaphylococciAntimicrobial Agents and Chemotherapy, 2002
- The responsibility of the pharmaceutical industryClinical Microbiology & Infection, 2001
- Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenesAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus SpeciesAntimicrobial Agents and Chemotherapy, 2001
- In vitro Activity of Moxifloxacin Compared to Other Fluoroquinolones against Different Erythromycin-Resistant Phenotypes of Group A β-hemolytic StreptococcusChemotherapy, 1999